Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B

International Journal of Antimicrobial Agents

Volumn 47, Issue 2, 2016, Pages 146-150

  Rigatto, Maria Helena ^a,b   Falci, Diego R ^b,c   Lopes, Natane T ^d   Zavascki, Alexandre P ^b,d  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Dose; Haemodialysis; Mortality; Polymyxin B

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; APACHE; ARTICLE; BODY WEIGHT; CHARLSON COMORBIDITY INDEX; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COHORT ANALYSIS; CONTINUOUS HEMODIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; RISK FACTOR; ADOLESCENT; ADVERSE EFFECTS; AGED; BACTERIAL INFECTIONS; CLINICAL TRIAL; COMPLICATION; KIDNEY FAILURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RENAL REPLACEMENT THERAPY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMYXIN B; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84956929787     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.11.007     Document Type: Article

References (19)

1. Z. Kassamali, and L. Danziger To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy 35 2015 17 21
2. R.L. Nation, T. Velkov, and J. Li Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59 2014 88 94
3. A.P. Zavascki Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside Expert Rev Anti Infect Ther 12 2014 531 533
4. A.M. Sandri, C.B. Landersdorfer, J. Jacob, M.M. Boniatti, M.G. Dalarosa, D.R. Falci, and et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens Clin Infect Dis 57 2013 524 531
5. A.M. Sandri, C.B. Landersdorfer, J. Jacob, M.M. Boniatti, M.G. Dalarosa, D.R. Falci, and et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis J Antimicrob Chemother 68 2013 674 677
6. L.S. Elias, D. Konzen, J.M. Krebs, and A.P. Zavascki The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic J Antimicrob Chemother 65 2010 2231 2237
7. M.H. Rigatto, T.F. Behle, D.R. Falci, T. Freitas, N.T. Lopes, M. Nunes, and et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study J Antimicrob Chemother 70 2015 1552 1557
8. T.C. Horan, M. Andrus, and M.A. Dudeck CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting Am J Infect Control 36 2008 309 332
9. W.A. Knaus, E.A. Draper, D.P. Wagner, and J.E. Zimmerman APACHE II: A severity of disease classification system Crit Care Med 13 1985 818 829
10. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
11. R.C. Bone, R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knaus, and et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 101 1992 1644 1655
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Document M100-S21 2011 CLSI Wayne, PA
13. R.V. Dudhani, J.D. Turnidge, K. Coulthard, R.W. Milne, C.R. Rayner, J. Li, and et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models Antimicrob Agents Chemother 54 2010 1117 1124
14. R.V. Dudhani, J.D. Turnidge, R.L. Nation, and J. Li fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models J Antimicrob Chemother 65 2010 1984 1990
15. M.P. Pai Polymyxin B dosing in obese and underweight adults Clin Infect Dis 57 2013 1785
16. C.B. Landersdorfer, R.L. Nation, A. Forrest, A.M. Sandri, and A.P. Zavascki Reply to Pai Clin Infect Dis 57 2013 1786
17. F.F. Tuon, M.H. Rigatto, C.K. Lopes, L.K. Kamei, J.L. Rocha, and A.P. Zavascki Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium Int J Antimicrob Agents 43 2014 349 352
18. C.H. Kvitko, M.H. Rigatto, A.L. Moro, and A.P. Zavascki Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia J Antimicrob Chemother 66 2011 175 179
19. B.C. Nelson, D.P. Eiras, A. Gomez-Simmonds, A.S. Loo, M.J. Satlin, S.G. Jenkins, and et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods Antimicrob Agents Chemother 59 2010 7000 7006